Penny M. Heaton

4.4k total citations
41 papers, 1.7k citations indexed

About

Penny M. Heaton is a scholar working on Infectious Diseases, Cardiology and Cardiovascular Medicine and Hepatology. According to data from OpenAlex, Penny M. Heaton has authored 41 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Infectious Diseases, 15 papers in Cardiology and Cardiovascular Medicine and 11 papers in Hepatology. Recurrent topics in Penny M. Heaton's work include Viral gastroenteritis research and epidemiology (24 papers), Viral Infections and Immunology Research (15 papers) and Hepatitis Viruses Studies and Epidemiology (11 papers). Penny M. Heaton is often cited by papers focused on Viral gastroenteritis research and epidemiology (24 papers), Viral Infections and Immunology Research (15 papers) and Hepatitis Viruses Studies and Epidemiology (11 papers). Penny M. Heaton collaborates with scholars based in United States, Finland and Belgium. Penny M. Heaton's co-authors include Michael J. Dallas, Michelle G. Goveia, Max Ciarlet, H. F. Clark, Paul A. Offit, Mark J. DiNubile, Robbin Itzler, Timo Vesikari, John W. Boslego and Penelope H. Dennehy and has published in prestigious journals such as JAMA, Gastroenterology and PLoS ONE.

In The Last Decade

Penny M. Heaton

41 papers receiving 1.7k citations

Peers

Countries citing papers authored by Penny M. Heaton

Since Specialization

Citations

This map shows the geographic impact of Penny M. Heaton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Penny M. Heaton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Penny M. Heaton more than expected).

Fields of papers citing papers by Penny M. Heaton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Penny M. Heaton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Penny M. Heaton. The network helps show where Penny M. Heaton may publish in the future.

Co-authorship network of co-authors of Penny M. Heaton

This figure shows the co-authorship network connecting the top 25 collaborators of Penny M. Heaton. A scholar is included among the top collaborators of Penny M. Heaton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Penny M. Heaton. Penny M. Heaton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Successes and Opportunities during the Pandemic: Reflections and Revelations from a Vaccine Development Perspective 2023 ·Clinical Pharmacology & Therapeutics ·Penny M. Heaton, Kavitha Palaniappan, (unknown), Silke Vogel, John C. W. Lim	2
2	Challenges of Developing Novel Vaccines With Particular Global Health Importance 2020 ·Frontiers in Immunology ·Penny M. Heaton	38
3	Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study 2018 ·The Lancet Global Health ·Dimitrios Gouglas, Tung Thanh Le, Klara Henderson, Aris Kaloudis, (unknown), (unknown), James M. Robinson, Penny M. Heaton, John‐Arne Røttingen	150
4	Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen) 2011 ·Human Vaccines ·Penelope H. Dennehy, Timo Vesikari, David O. Matson, Robbin Itzler, Michael J. Dallas, Michelle G. Goveia, Mark J. DiNubile, Penny M. Heaton, Max Ciarlet	29
5	Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5) 2010 ·BMC Pediatrics ·Robbin Itzler, Gary G. Koch, David O. Matson, Leif Gothefors, Pierre Van Damme, Mark J. DiNubile, Penny M. Heaton	10
6	Age Dependence of the Risk of Intussusception Following Tetravalent Rhesus-Human Reassortant Rotavirus Tetravalent Vaccine: Is It Beyond Doubt? 2010 ·American Journal of Epidemiology ·(unknown), Joseph F. Heyse, Penny M. Heaton, Barbara J. Kuter	4
7	Safety and Immunogenicity of a Recombinant Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Healthy Adults 2009 ·Penny M. Heaton	1
8	A Trivalent Virus-Like Particle Vaccine Elicits Protective Immune Responses against Seasonal Influenza Strains in Mice and Ferrets 2009 ·PLoS ONE ·Ted M. Ross, (unknown), Corey J. Crevar, Kirsten Schneider-Ohrum, Penny M. Heaton, Rick A. Bright	73
9	Concomitant Use of the 3-Dose Oral Pentavalent Rotavirus Vaccine With a 3-Dose Primary Vaccination Course of a Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Inactivated Polio-Haemophilus influenzae Type b Vaccine 2009 ·The Pediatric Infectious Disease Journal ·Max Ciarlet, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Penny M. Heaton, (unknown), Thomas Rose, Dieter Y. Koller, Pierre Van Damme, F. Schödel	28
10	H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses 2008 ·Vaccine ·Kutubuddin Mahmood, Rick A. Bright, Nutan Mytle, Donald M. Carter, Corey J. Crevar, Jenna E. Achenbach, Penny M. Heaton, Terrence M. Tumpey, Ted M. Ross	109
11	ROTATEQ® REDUCED HOSPITALIZATIONS AND EMERGENCY DEPARTMENT VISITS FOR ROTAVIRUS ACUTE GASTROENTERITIS: ASSESSING THE ROBUSTNESS OF THE RESULTS 2008 ·Archives of Disease in Childhood ·Timo Vesikari, Robbin Itzler, David O. Matson, Michele L. Coia, J.R. Cook, Mark J. DiNubile, Penny M. Heaton, Joseph F. Heyse, (unknown), Max Ciarlet	1
12	Concomitant Use of the Oral Pentavalent Human-Bovine Reassortant Rotavirus Vaccine and Oral Poliovirus Vaccine 2008 ·The Pediatric Infectious Disease Journal ·Max Ciarlet, (unknown), (unknown), (unknown), Penny M. Heaton, Keith Gottesdiener, José Luis Arredondo-Garcı́a, F. Schödel	65
13	Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries) 2007 ·International Journal of Infectious Diseases ·Timo Vesikari, Robbin Itzler, David O. Matson, Mathuram Santosham, C D C Christie, Michele L. Coia, J.R. Cook, Gary G. Koch, Penny M. Heaton	80
14	The Pentavalent Rotavirus Vaccine: Discovery to Licensure and Beyond 2007 ·Clinical Infectious Diseases ·Penny M. Heaton, Max Ciarlet	60
15	Safety and Efficacy of the Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine in Healthy Premature Infants 2007 ·The Pediatric Infectious Disease Journal ·Michelle G. Goveia, Zoe Rodriguez, Michael J. Dallas, Robbin Itzler, John W. Boslego, Penny M. Heaton, Mark J. DiNubile	83
16	The New Pentavalent Rotavirus Vaccine Composed of Bovine (Strain WC3) -Human Rotavirus Reassortants 2006 ·The Pediatric Infectious Disease Journal ·H. F. Clark, Paul A. Offit, Stanley A. Plotkin, Penny M. Heaton	50
17	Development of a Pentavalent Rotavirus Vaccine against Prevalent Serotypes of Rotavirus Gastroenteritis 2005 ·The Journal of Infectious Diseases ·Penny M. Heaton, Michelle G. Goveia, Jacqueline M. Miller, Paul A. Offit, H. F. Clark	66
18	Rotavirus Immunoglobulin A Responses Stimulated by Each of 3 Doses of a Quadrivalent Human/Bovine Reassortant Rotavirus Vaccine 2004 ·The Journal of Infectious Diseases ·Richard L. Ward, David I. Bernstein, Vicki E. Smith, D. S. Sander, Alan Shaw, Joseph Eiden, Penny M. Heaton, Paul A. Offit, H. F. Clark	39
19	Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants 2004 ·The Journal of Pediatrics ·H. F. Clark, David I. Bernstein, Penelope H. Dennehy, Paul A. Offit, Michael E. Pichichero, John J. Treanor, Richard L. Ward, David L. Krah, Alan Shaw, Michael J. Dallas, (unknown), Joseph Eiden, Nathalie Ivanoff, Karen M. Kaplan, Penny M. Heaton	116
20	Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation 2003 ·The Pediatric Infectious Disease Journal ·H. F. Clark, Carl J. Burke, David B. Volkin, Paul A. Offit, Richard L. Ward, Joseph Bresee, Penelope H. Dennehy, Willis M. Gooch, (unknown), (unknown), Emmanuel B. Walter, Barbara Watson, David L. Krah, Michael J. Dallas, (unknown), Karen M. Kaplan, Penny M. Heaton	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact